Abstract:Antibody-drug conjugates (ADCs) are designed by chemically linking highly potent cytotoxic small molecule drugs to monoclonal antibodies of unique specificity for targeted destruction of cancer cells. This innovative class of molecules incurs unique developmental challenges due to its structural complexity of having both small molecule and protein components. The stability of the small molecule payload on the ADC is a critical attribute as it directly relates to product efficacy and patient safety. This study describes the use of an end-to-end automated workflow for effective and robust characterization of the small molecule drug while it is conjugated to the antibody. In this approach, online deconjugation was accomplished by an autosampler user defined program and 1 D size exclusion chromatography was utilized to provide separation between small molecule and protein species. The small molecule portion was then trapped and sent to the 2 D for separation and quantification by reversed-phase liquid chromatography with identification of impurities and degradants by mass spectrometry. The feasibility of this system was demonstrated on an ADC with a disulfide-based linker. This fully automated approach avoids tedious sample preparation that may lead to sample loss and large assay variability. Under optimized conditions, the method was shown to have excellent specificity, sensitivity (LOD of 0.036 μg/mL and LOQ of 0.144 μg/mL), linearity (0.04 – 72.1 μg/mL), precision (system precision %RSD of 1.7 and method precision %RSD of 3.4), accuracy (97.4% recovery), stability-indicating nature, and was successfully exploited to analyze the small molecule drug on a panel of stressed ADC samples. Overall, the workflow established here offers a powerful analytical tool for profiling the in-situ properties of small molecule drugs conjugated to antibodies and the obtained information could be of great significance for guiding process/formulation development and understanding pharmacokinetic/pharmacodynamic behavior of ADCs.

Bioanalytical assays for pharmacokinetic and biodistribution study of Antibody-Drug Conjugates

50th Anniversary Celebration Collection Special Section on New and Emerging Areas and Technologies in Drug Metabolism and Disposition, Part I-Minireview Bioanalytical Assays for Pharmacokinetic and Biodistribution Study of Antibody-Drug Conjugates

[Bioanalysis in the development of antibody-drug conjugates]

Analytical Tools for Antibody–drug Conjugates: from in Vitro to in Vivo

In situ quantitative bioanalysis of monomethyl auristatin E-conjugated antibody-drug conjugates by flow cytometry.

Bibliometric analysis of antibody-drug conjugates

Enhanced Pharmacokinetic Bioanalysis of Antibody–drug Conjugates using Hybrid Immunoaffinity Capture and Microflow LC-MS/MS

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Automated Online Deconjugation of Antibody-Drug Conjugate for Small Molecule Drug Profiling

A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species

A general perspective for the conduct of radiolabelled distribution, metabolism, and excretion studies for antibody-drug conjugates

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

Conjugation Site Analysis of Antibody-Drug-conjugates (adcs) by Signature Ion Fingerprinting and Normalized Area Quantitation Approach Using Nano-Liquid Chromatography Coupled to High Resolution Mass Spectrometry.

Application of Pharmacometrics in Advancing the Clinical Research of Antibody-Drug Conjugates: Principles and Modeling Strategies

Antibody-drug conjugates: Principles and opportunities

ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability

Site-Specific Stability Evaluation of Antibody-Drug Conjugate in Serum Using a Validated Liquid Chromatography-Mass Spectrometry Method

The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies